Search clinical trials for: Dyspepsia, gastrointestinal, tegaserod

Total 28 results

Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
Novartis

Completed

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Dyspepsia

United States
Novartis
Mayo Clinic

Withdrawn

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

Constipation and Dyspepsia
Novartis
University of Michigan; Temple University

Terminated

Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

Chronic Constipation

United States
Novartis

Completed

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

Constipation

United States
Braintree Laboratories

Completed

Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation

Constipation

United States
Novartis

Terminated

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

Diabetes | Gastroparesis

United States
Novartis

Terminated

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Opioid-induced Constipation

United States
Novartis

Terminated

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Diabetic Gastropathy

Switzerland
Novartis

Terminated

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Opioid-induced Constipation

United States, China, Egypt, Singapore, Taiwan, Venezuela
Novartis

Terminated

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Constipation

United States
Novartis Pharmaceuticals

Terminated

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Constipation Predominant | Irritable Bowel Syndrome (IBS-C)

United States
Hospital Authority, Hong Kong
Novartis

Terminated

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation

Constipation | Chronic Disease

China
Novartis

No longer available

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation
Novartis

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroespohageal Reflux Disease

United States
Hospital Authority, Hong Kong
Novartis Pharmaceuticals

Unknown

Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method

Constipation

China
Fudan University

Unknown

Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage

Pneumonia | Cerebral Hemorrhage | Lung Infection

China
Novartis

Completed

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Dyspepsia

United States
Novartis

Completed

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Dyspepsia

United States
Novartis

Completed

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

Chronic Constipation
Novartis

Completed

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Dyspepsia

United States
Novartis

Completed

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Dyspepsia

United States
Novartis

Completed

An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation

Constipation

Switzerland
Novartis

Completed

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

Chronic Constipation

Switzerland
Novartis

Completed

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Gastroesophageal Reflux Disease (GERD)

United States
Novartis

Completed

Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS

IBS-C and IBS With Mixed Bowel Habits
Novartis

Completed

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Gastroesophageal Reflux Disease (GERD)

United States
Novartis

Completed

The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.

Dyspepsia | Heartburn

United States

3

Subscribe